Pharmacotherapy in conjunction with lifestyle for the treatment of obesity complications, is it enough?
- PMID: 30740430
- PMCID: PMC6330601
- DOI: 10.21037/atm.2018.11.60
Pharmacotherapy in conjunction with lifestyle for the treatment of obesity complications, is it enough?
Conflict of interest statement
Conflicts of Interest: CW le Roux serves on advisory boards for Novo Nordisk, Johnson & Johnson, GI Dynamics, Fractyl, Keyron and Herbalife. W Al-Najim has no conflicts of interest to declare.
Comment on
-
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293771 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources